121359-48-6

Basic information

• Product Name: 2-(TRIBUTYLSTANNYL)THIAZOLE
• Synonyms: 2-(TRIBUTYLSTANNYL)THIAZOLE;2-(Tributylstannyl)-1,3-thiazole;2-(Tri-n-butylstannyl)thiazole, 96%;2-(Tributylstannyl)-1,3-thiazole 95+%;2-Tributylstaylthiazole;(1,3-Thiazol-2-yl)tributylstannane;Thiazole,2-(tributylstannyl)-;2-(Tributyltin)thiazole
• CAS NO: 121359-48-6
• Molecular Formula: C₁₅H₂₉NSSn
• Molecular Weight: 374.17
• Product Categories: Organostannes;Thiazole;Tributylstanny;Organometallic Reagents;Organotin;Organotins;Chemical Synthesis;Organometallic Reagents
• Mol File: 121359-48-6.mol

Chemical Properties

• Melting Point: 224-225℃
• Boiling Point: 307-309 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.1900 g/mL at 25 °C(lit.)
• Vapor Pressure: 4.23E-05mmHg at 25°C
• Refractive Index: n20/D 1.5200(lit.)
• Storage Temp.: Keep Cold
• Solubility: Not miscible or difficult to mix.
• PKA: 2.73±0.10(Predicted)
• CAS DataBase Reference: 2-(TRIBUTYLSTANNYL)THIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(TRIBUTYLSTANNYL)THIAZOLE(121359-48-6)
• EPA Substance Registry System: 2-(TRIBUTYLSTANNYL)THIAZOLE(121359-48-6)

Safety Data

• Hazard Codes: T,N,Xi
• Statements: 21-25-36/38-48/23/25-50/53
• Safety Statements: 35-36/37/39-45-60-61
• RIDADR: UN 2788 6.1/PG 2
• WGK Germany: 3
• HazardClass: IRRITANT, KEEP COLD, TOXIC
• Hazardous Substances Data: 121359-48-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(TRIBUTYLSTANNYL)THIAZOLE is used as a reagent for the arylation of thiazole by Stille cross-coupling for the synthesis of biologically active compounds, including pharmaceuticals with potential therapeutic applications.
Used in Organic Synthesis:
2-(TRIBUTYLSTANNYL)THIAZOLE is used as a reagent for the arylation of thiazole by Stille cross-coupling in the preparation of various organic compounds, such as heterocycles and natural products, which are important in material science and medicinal chemistry.
Used in Chemical Research:
2-(TRIBUTYLSTANNYL)THIAZOLE is used as a reagent for the arylation of thiazole by Stille cross-coupling in academic and industrial research settings to explore new reaction pathways, develop novel synthetic methods, and create innovative chemical entities.

InChI:InChI=1/3C4H9.C3H2NS.Sn/c3*1-3-4-2;1-2-5-3-4-1;/h3*1,3-4H2,2H3;1-2H;/rC15H29NSSn/c1-4-7-12-18(13-8-5-2,14-9-6-3)15-16-10-11-17-15/h10-11H,4-9,12-14H2,1-3H3

Upstream product

• 1461-22-9 tributyltin chloride 
• 79265-30-8 2-(trimethylsilyl)thiazole 
• 3034-53-5 2-bromo-1,3-thiazole 

Downstream Products

• 251635-71-9 1-(2-cyanophenyl)-6,6-dimethyl-3-(thiazol-2-yl)-4,5,6,7-tetrahydroindol-4-one 
• 1059597-25-9 benzyl 4-methyl-1-oxo-1-(thiazol-2-yl)pentan-2-ylcarbamate 
• 1172128-04-9 5-fluoro-4-(thiazol-2-yl)-7-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 1118018-79-3 4-[3-(1,3-thiazol-2-yl)imidazo[1,2-a]pyrimidin-2-yl]benzaldehyde 
• 1118018-96-4 4-(5-Thiazol-2-yl-imidazo[2,1-b]thiazol-6-yl)benzaldehyde 
• 1046793-47-8 2-(5-bromo-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazole 
• 1035170-84-3 N-[2-methyl-5-[4-[4-(1,3-thiazol-2-yl)phenyl]piperidine-1-carbonyl]phenyl]methanesulfonamide 
• 1024611-39-9 N'-(2-cyano-4-thiazol-2-yl-phenyl)-N,N-dimethyl-formamidine 
• 935506-71-1 3-(2,4-Dichlorophenyl)-1-methyl-6-(1,3-thiazol-2-yl)-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one 
• 1001412-25-4 [3-methyl-4-(7-thiazol-2-yl-1H-pyrrolo[2,3-c]pyridine-3-sulfonyl)-piperazin-1-yl]phenylmethanone 
• 676491-18-2 4-(1-Phenyl-1-(thiazol-2-yl)-methylene)-piperidine-1-carboxylic Acid tert-butyl Ester 
• 676490-68-9 1-[4-(1-phenyl-1-(thiazol-2-yl)-methylene)-piperidin-1-yl]-2-(4,7-dimethoxy-6-azaindol-3-yl)-ethane-1,2-dione 
• 943925-53-9 3-benzyloxycarbonylamino-5-thiazol-2-yl-benzoic acid methyl ester 

Relevant articles and documents

Morphology Driven by Molecular Structure of Thiazole-Based Polymers for Use in Field-Effect Transistors and Solar Cells

The effects of the molecular structure of thiazole-based polymers on the active layer morphologies and performances of electronic and photovoltaic devices were studied. Thus, thiazole-based conjugated polymers with a novel thiazole-vinylene-thiazole (TzVTz) structure were designed and synthesized. The TzVTz structure was introduced to extend the π conjugation and coplanarity of the polymer chains. By combining alkylthienyl-substituted benzo[1,2-b:4,5-b′]dithiophene (BDT) or dithieno[2,3-d:2′,3′-d′]benzo[1,2-b:4,5-b′]dithiophene (DTBDT) electron-donating units and a TzVTz electron-accepting unit, enhanced intermolecular interactions and charge transport were obtained in the novel polymers BDT-TzVTz and DTBDT-TzVTz. With a view to using the polymers in transistor and photovoltaic applications, the molecular self-assembly in and their nanoscale morphologies of the active layers were controlled by thermal annealing to enhance the molecular packing and by introducing a diphenyl ether solvent additive to improve the miscibility between polymer donors and [6,6]phenyl-C71-butyric acid methyl ester (PC71BM) acceptors, respectively. The morphological characterization of the photoactive layers showed that a higher degree of π-electron delocalization and more favorable molecular packing in DTBDT-TzVTz compared with in BDT-TzVTz leads to distinctly higher performances in transistor and photovoltaic devices. The superior performance of a photovoltaic device incorporating DTBDT-TzVTz was achieved through the superior miscibility of DTBDT-TzVTz with PC71BM and the improved crystallinity of DTBDT-TzVTz in the nanofibrillar structure.

BORON-CONTAINING ORGANIC SEMICONDUCTOR COMPOUND AND PRODUCING METHOD OF THE SAME

The present invention relates to a boron-containing organic semiconductor compound which includes a boron derivative, and to a method for producing the compound. According to an embodiment of the present invention, the boron-containing compound exhibits high oxidation resistance and thermal stability.COPYRIGHT KIPO 2017

DYE, AND PHOTOELECTRIC CONVERSION ELEMENT AND PHOTOELECTROCHEMICAL CELL USING THE SAME

PROBLEM TO BE SOLVED: To provide a photoelectric conversion element and photoelectrochemical cell that achieves a high photoelectric conversion efficiency and in addition that has excellent durability, as well as to provide a dye used therein. SOLUTION: Provided is a dye represented by formula: MLt2L1. (M is ruthenium, osmium, iron, rhenium or technetium; Lt2 is a tridentate ligand represented by the formula (2-2); and L1 is a tridentate ligand of bis-pyrazole-substituted pyridine compound.). (R1 and R2 is -COOH or the like, La is a single bond or an arylene group; n1 is an integer of 1 to 3; n2 is an integer of 1 to 4; R6 is a substituent containing a C1 to 30 alkyl group or the like; and n6 is an integer of 1 to 5.). SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from -N= etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from -CH 2 - etc., and R 2 is selected from C 1-6 alkyl etc.

Di-thiazolyl-benzodiazole based sensitizers and their use in photovoltaic cell

Described herein are D-π-A type sensitizers of the formula (I) or (II) having a novel central π-conjugated unit di-thiazolyl-benzodiazole and dye-sensitized electrodes including a substrate having an electrically conductive surface, an oxide semiconductor film formed on the conductive surface, and the above sensitizer of formula (I) or (II), as specified above, supported on the film. A solar cell includes the above electrode, a counter electrode, and an electrolyte deposited there between. The sensitizers of formula (I) and (II) efficiently sensitize the semiconductor materials and show a high solar to electricity conversion efficiency.

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

p27 PROTEIN INDUCER

The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G1, G2, G3 and G8 are each independently selected from -N= etc., Ring G6 is selected from divalent aryl etc., A is selected from amino etc., G4 is selected from oxygen etc., G5 is selected from oxygen etc., G7 is selected from -CH2- etc., and R2 is selected from C1-6 alkyl etc.

NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY

The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from -N= etc., Y3 and Y4 are selected from -CH= etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY

A compound of the formula (I): wherein Z4, Z5 and Z9 each is independently carbon atom or nitrogen atom; Y is hydroxy, mercapto or amino; RA is a group of the formula: (wherein C ring is nitrogen-containing heteroaryl) has an inhibitory activity against integrase.